based packaging company AptarGroup’s Russian factory under temporary management by Danone’s former Russian arm — Meduza

Russian President Vladimir Putin has placed a 100% stake in Aptar Vladimir, a subsidiary of AptarGroup, under temporary management. Aptar Vladimir operates a plastic packaging plant in Russia. The temporary manager, H&N, is the legal entity behind Danone's nationalized Russian division. AptarGroup is a U.S.-based multinational company.

Original reporting
Published Sep 21, 2026, 3:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 3:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
based packaging company AptarGroup’s Russian factory under temporary management by Danone’s former Russian arm — Meduza — source image
Decision brief

The 30-second read

$APTBearishLow
01

Why it matters

The decree may lead to operational disruptions, potential write‑offs, and heightened risk perception for investors.

02

Market read

State seizure of foreign assets introduces new risk for multinational firms, prompting possible price adjustments.

03

What to watch

Potential compensation or legal recourse for AptarGroup could mitigate losses.

Relevance 6/10Novelty 7/10Timing: effective immediately

Background

AptarGroup, a US‑listed packaging solutions provider, owns a Russian plant now under temporary management by a former Danone entity.

Company-level read

Ticker impact

$APTBearishMedium confidence
Context

Russian decree places Aptar Vladimir, the Russian plant of AptarGroup, under temporary state management.

Expected impact

Downside pressure on APT as investors assess risk of asset seizure.

Evidence & confidence

State takeover of foreign-owned assets typically leads to uncertainty and possible write‑offs, prompting a negative market reaction.

Market effects

Packaging sector faces heightened geopolitical risk in Russia.

Russian market sees increased state control over foreign firms.

Signals broader trend of asset seizures affecting multinational companies.

Counterpoint

If the Russian plant contributes minimally to global revenue, the impact on APT may be limited.

Key entities

  • AptarGroup

    US‑listed packaging company (ticker APT).

  • Russian Government

    Issued decree placing foreign assets under temporary management.

Related articles

$APTMed

ALPHA PRO TECH, LTD. ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

ALPHA PRO TECH LTD (APT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ALPHA PRO TECH, LTD. ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Third Quarter Net Sales Increased by 12.3% to $16.6 Million, from $14.8 Million for the Third Quarter of 2025 Third Quarter Net Income Increased by 97.2% to $1.9 Million from $1.0 Million in the Prio

$ATRHighAI 8/10

Aptar Q3 2026 slides: broad growth, strong Pharma pipeline

AptarGroup (NYSE:ATR) reported Q3 2026 sales of $1.019B, up 6% YoY, with adjusted EPS of $1.52 beating estimates. Growth was seen across all segments, but margins were pressured. The Pharma segment grew 2% reported, 1% core, while Beauty grew 9% reported, 8% core, and Closures grew 11%. Management expects Q4 adjusted EPS of $1.39-$1.47, up 17% YoY.

$ATRMed

AptarGroup Inc (ATR) (Q3 2026) Earnings Call Highlights: Core Sales Grow 5% as Pharma

AptarGroup Inc (ATR) reported Q3 2026 core sales growth of 5% across all segments, with Pharma, Beauty, and Closures up 8%, 8%, and 11% respectively. Adjusted EPS was $1.52, down 6% YoY. Pharma growth was impacted by emergency medicine destocking, expected to affect full-year sales by $65M. Beauty and Closures margins declined due to operational challenges. CEO Gael Touya outlined plans for multi-year transformation in Beauty and reiterated long-term growth targets for Pharma.

$ATRMedAI 8/10

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup (ATR) reported Q3 earnings, highlighting growth in beauty, closures, and pharma sectors. Beauty core sales rose 8%, while closures saw 11% growth. Pharma developments include collaborations and acquisitions. The company recorded a $61.2M charge related to its Russian subsidiary. ATR forecasted Q4 adjusted EPS of $1.39-$1.47, up 17% YoY. Full-year capex is expected at $260M-$280M. Virginie Maes will lead Aptar Pharma starting January 1.